| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 9-21-26 |
Rob discussed Merck’s collaboration with Moderna and trial results combining the personalized cancer vaccine with Keytruda. [audio] | -0.5% | — | — |
| 2026-09-17 | MENTIONED | LOW | Rob Black Show Afternoon podcast 9-17-26 |
Merck was cited as a large pharmaceutical partner of smaller biotech companies. [audio] | +0.6% | — | — |
| 2026-09-08 | MENTIONED | LOW | Rob Black Show Afternoon podcast 9-8-26 |
Merck is named alongside Pfizer and Novartis as a drug stock Rob cannot properly analyze. [audio] | -2.6% | — | — |
| 2026-08-26 | MENTIONED | LOW | Rob Black Show Afternoon podcast 8-26-26 |
Merck is Moderna's partner on the personalized cancer vaccine, with Keytruda as the combination and comparator in the Phase 3 trial. [audio] | -1.0% | -2.2% | — |
| 2026-08-20 | MENTIONED | MEDIUM | Rob Black Show Afternoon podcast 8-20-26 |
Merck's Keytruda was described as the key that unlocks the immune response paired with Moderna's personalized cancer vaccine. [audio] | +0.4% | -0.8% | — |
| 2026-08-20 | BUY | HIGH | Rob Black Show Markets Drop Hurt By Rising Treasury Yields |
Merck gained 9% on positive phase three cancer vaccine data with Moderna, drawing an RBC downgrade and a Morgan Stanley upgrade, with Keytruda's franchise potentially extended enormously. [audio] | +0.4% | -0.8% | — |
| 2026-08-19 | BUY | HIGH | Rob Black Show Afternoon podcast 8-19-26 |
Merck rose 12% as its blockbuster Keytruda paired with Moderna's mRNA vaccine, potentially extending its cancer franchise significantly. [audio] | +0.6% | -2.9% | — |
| 2026-08-19 | MENTIONED | HIGH | Rob Black Show Stock Market Is Shrugging Off Geopolitical Risks |
Merck rose 7% as co-developer of Moderna's cancer vaccine. [audio] | +0.6% | -2.9% | — |
| 2026-08-04 | SELL | MEDIUM | Rob Black Show Oil Prices Dropped Amid Optimism |
Merck topped expectations and hiked guidance but Rob said he'll pass because there's nothing sexy and no growth there beyond the dividend. [audio] | +1.9% | +19.0% | — |
| 2026-07-20 | MENTIONED | LOW | Rob Black Show Afternoon podcast 7-20-26 |
Merck's Keytruda discussed as best-selling drug in the world; patents peeling off in 2028. [audio] | +5.1% | +22.3% | — |
| 2026-07-20 | WATCH | LOW | Rob Black Show Oil Prices Fluctuated |
Merck mentioned as a potential future acquirer in the psychedelic medicine space. [audio] | +5.1% | +22.3% | — |
| 2026-07-17 | MENTIONED | LOW | Rob Black Show Financial Planning That You Never Knew |
Merck cited as a potential future entrant into the psychedelic medicine market. [audio] | +2.8% | +6.5% | — |
| 2026-06-26 | MENTIONED | HIGH | Rob Black Show Afternoon podcast 6-25-26 |
Merck agreed to acquire Bio-Techne for $73 a share. [audio] | +0.7% | +1.9% | +15.7% |
| 2026-06-24 | MENTIONED | LOW | Rob Black Show Oil Prices Fall Four Percent |
Merck mentioned as a mainstay stock that was positive during market rotation. [audio] | +4.0% | +8.7% | +25.9% |
| 2026-06-23 | MENTIONED | LOW | Rob Black Show Afternoon podcast 6-23-26 |
Merck saw gains as well. [audio] | +7.4% | +9.1% | +25.7% |
| 2026-06-04 | MENTIONED | LOW | Rob Black Show Broadcom Problems |
Merck Animal Health Division produces Exult Cattle CA1, approved to treat screw worm infestations. [audio] | +0.4% | +8.5% | +27.0% |
| 2026-05-29 | BUY | MEDIUM | Rob Black Show Thinking About A Shopping List |
The host recommends buying Merck, citing a low P/E ratio and the potential for AI-driven growth. [audio] | +1.7% | +9.2% | +26.9% |
| 2026-05-22 | MENTIONED | MEDIUM | Rob Black Show Strategy Show For Memorial Day Weekend |
Merck saw positive phase three results for a lung cancer treatment, trading up about 4.5%. [audio] | -3.0% | -6.3% | +22.6% |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Afternoon podcast 5-19-26 |
Host lists Merck as one of the top 10 stocks in the year 2000. [audio] | +4.8% | +0.4% | +19.9% |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Stocks Slide Under Pressure From Higher Rates |
EMD Serono (part of Merck KGaA) is listed as one of the pharmaceutical companies offering discounts on TrumpRx. [audio] | +4.8% | +0.4% | +19.9% |
| 2026-05-11 | MENTIONED | LOW | Rob Black Show Fresh Record Bolstered By Key Tech Stocks |
Host notes Merck is up 1.7% and that the market is mixed. [audio] | +1.1% | +7.0% | +16.4% |
| 2026-05-07 | MENTIONED | LOW | Rob Black Show Oil Continues Pullback |
Merck is mentioned in the context of past performance. [audio] | +1.0% | +7.6% | +15.1% |
| 2026-04-27 | MENTIONED | MEDIUM | Rob Black Show The Performance Of Semiconductor Stocks |
Host recalls a lesson from investing in Merck related to Viagra. [audio] | +2.6% | +9.1% | +19.8% |